Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Figure 4

Comparison case in point of MPS, MPS, and tTDS for mutation tracking: PIK3CA mutation H1047R could be detected in plasma and in the FFPE pretreatment biopsy by MPS, ddPCR, and tTDS. However, ddPCR allowed the detection of such mutation only at baseline, whereas by tTDS we could track the presence of H1047R six months before relapse.